Palonosetoron+Aprepitant+Dexamethasone Therapy in patients receiving moderately emetogenic anticancer drugs (EJCG-1001)
Phase 2
Recruiting
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000006498
- Lead Sponsor
- East Japan Chesters Group (EJCG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1)Severe complications 2)Symptomatic brain meta 4) Massive pleural or abdominal effusion 5) Intestinal paralysis or ileus 7)Hypersensitivity for PaIonosetron, Aprepitant, Dexamethasone 9) Pregnant or lactating 10) Other patients who are unfit for the study as determined by the attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete response rate in chemotherapy of CBDCA
- Secondary Outcome Measures
Name Time Method